Faeth Therapeutics stock as Roche joins PIKTOR breast cancer trial
Published on 11/19/2026 at 02:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRoche collaboration expands PIKTOR path
- Faeth will sponsor a Phase 1b/2 study of PIKTOR with Roche's investigational medicine giredestrant in advanced HR+/HER2-negative breast cancer.
- Faeth retains all rights to PIKTOR while Roche supplies giredestrant for the trial.
- Interim data from the breast cancer study is anticipated in 2027.
Faeth Therapeutics announced on November 16, 2026, that it had entered a clinical trial collaboration and supply agreement with F. Hoffmann-La Roche Ltd. The company release says the partnership will evaluate PIKTOR with the investigational medicine giredestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer.
Roche supplies the combination partner
Faeth will sponsor and conduct the Phase 1b/2 FTH-PIK-101 study. Roche will supply giredestrant for use in the trial, while Faeth retains all rights to PIKTOR.
PIKTOR is an investigational all-oral combination of serabelisib and sapanisertib designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway. The first patient in the breast cancer study was dosed in April 2026, and interim data is anticipated in 2027.
Clinical-stage oncology focus
Faeth Therapeutics is a U.S.-based clinical-stage biotechnology company focused on multi-node inhibition of oncogenic pathways. Its lead program PIKTOR is being developed for endometrial and breast cancer, with an all-oral treatment approach. The company remains an early-development specialist rather than a commercial pharmaceutical business, with its value tied to clinical progress and future study results.
Faeth Therapeutics at a glance
- Company: Faeth Therapeutics, Inc.
- Ticker: FTH
- Exchange: Nasdaq
- Business: Clinical-stage oncology biotechnology
- Lead program: PIKTOR
The broader U.S. market environment remains relevant for investors following the S&P 500.
